Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Extavia

- PMLiVE

Mesoblast’s stem cell therapy fails to meet primary endpoint in COVID-19 study

Remestemcel-L was being studied in patients with COVID-19-related acute respiratory distress

- PMLiVE

Novartis receives FDA breakthrough therapy designation for rare disease med

The Swiss pharma company is eyeing approval in PNH and C3G indications

- PMLiVE

Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib

Investigational drug beat Pfizer's Bosulif in phase 3 study

Bayer symbol

Bayer strengthens cell and gene therapy focus with new platform

Platform builds on previous acquisition deals for AskBio and BlueRock

- PMLiVE

Biogen signs $3.1bn deal with Sage for potential depression therapies

Zuranolone already has a breakthrough therapy designation from the US FDA

- PMLiVE

Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer

Drug approved in combination with Merck's KGaA's Erbitux

- PMLiVE

Novartis and smartpatient launch app experience for wet AMD patients

Wet AMD is the leading cause of severe vision loss and legal blindness in people over the age of 65

- PMLiVE

NICE launches consultation on its methods of drug evaluation

Public consultation launched on Friday 6 November

- PMLiVE

FDA advisory committee overwhelmingly votes no on Biogen’s aducanumab

Path to approval looks increasingly difficult for potential Alzheimer’s treatment

- PMLiVE

Novartis’ canakinumab failed to improve survival in COVID-19 study

Swiss pharma company had been studying drug in hospitalised COVID-19 patients

- PMLiVE

FDA briefing documents back Biogen’s Alzheimer’s drug aducanumab

Documents show the efficacy data for the drug as being ‘exceptionally persuasive’

- PMLiVE

NICE – but not enough

Why evidence is better than assumption when executing commercial strategy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links